Search

everythinglearnresearchcommunity

for

Search:↓

YAP and TAZ proteins are necessary for the development of two types of skin cancer.

Tofacitinib may help treat severe hair loss, but more research is needed.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Voglibose may help treat skin hyperpigmentation safely.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

The treatment combination is effective and generally safe for lung cancer.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Nilotinib can cause generalized keratosis pilaris.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

A woman's hair turned white after taking a cancer drug called dasatinib.

Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

A man developed a skin cancer called folliculotropic mycosis fungoides after a kidney transplant.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Upadacitinib may effectively treat alopecia areata without side effects.

Some blood pressure medications are linked to a higher risk of skin cancer.